Genital Herpes Vaccine Shows Promise

A new genital herpes vaccine reduced viral shedding and lesions during outbreaks, according to new research presented at the American Academy of Dermatology 74th Annual Meeting.

The vaccine, known as GEN-003, is designed to induce T-cell and B-cell immune responses.
____________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
A Collection of Herpes Manifestations and Herpes-Associated Syndromes
Breakthrough Vaccine May Protect Against Herpes Virus
____________________________________________________________________________________________________________________________________________________________________

Researchers funded by Genocea Biosciences randomly assigned 310 patients with herpes simplex virus 2 infection to 1 of 7 groups receiving either 30 μg of antigen with 25, 50, or 75 μg of adjuvant; 60 μg of antigen with 25, 50, or 75 μg of adjuvant; or placebo.

Patients received 3 doses of the vaccine 3 weeks apart and conducted genital swabs before the first dose, immediately after the third dose, and after 6 months and 12 months after the third dose.

Researchers also collected blood samples at 6 months and 12 months.

After 6 months, patients had less viral shedding and lesions during outbreaks. The group that was administered 60 μg of antigen and 75 μg of adjuvant saw the most significant reduction in viral shedding (55%).

In addition, only mild side effects were reported, including myalgia, fatigue, and pain or swelling at the injection site.

Researchers say the results from the 12-month samples will be available later this year.

—Amanda Balbi

Reference:

Tucker, ME. Investigational therapeutic genital herpes vaccine promising. Medscape. Published online March 5, 2016. http://www.medscape.com/viewarticle/859925.